{"product_id":"bmrn-bcg-matrix","title":"(BMRN) BioMarin Pharmaceutical Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BioMarin Pharmaceutical Inc. BCG Matrix is a ready-made strategic tool used to assess the company’s products or business units across the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVoxzogo, first-in-class achondroplasia therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoxzogo is BioMarin Pharmaceutical Inc.'s main growth engine heading into end-2025, with achondroplasia affecting roughly 1 in 15,000 to 1 in 25,000 births and still underdiagnosed in many markets. It was the first approved treatment for achondroplasia, giving BioMarin strong first-mover control as the patient pool expands. As diagnosis, reimbursement, and access improve, Voxzogo should keep widening its reach and supporting BioMarin's top line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVoxzogo, global rollout and label expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVoxzogo is BioMarin Pharmaceutical Inc.'s clearest Star: 2024 revenue reached about $618 million, up 9% year over year, and the brand kept scaling beyond the U.S. It is approved in major markets including the U.S., EU, Japan, and China, with more countries and treated patients supporting the growth case. Ongoing label expansion in younger and broader achondroplasia groups should keep demand rising.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePalynziq, severe PKU franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePalynziq stayed a Star in 2025, with BioMarin keeping it as a key growth drug in severe PKU. The franchise targets a narrow but expandable adult PKU pool, and uptake keeps rising as more patients move into specialty treatment. In 2025, its growing use helped BioMarin deepen rare-disease sales momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePalynziq, only commercial PAL enzyme therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePalynziq is BioMarin Pharmaceutical Inc.’s only commercial phenylalanine ammonia lyase (PAL) enzyme therapy, and its pegvaliase mechanism gives it a clear edge in phenylketonuria, a rare disease affecting about 1 in 10,000 to 1 in 15,000 births. That differentiation supports share in a niche with limited direct competition, and the brand can stay in Star territory if 2025\/2026 patient starts and long-term persistence remain strong.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnly commercial PAL enzyme therapy\u003c\/li\u003e\n\u003cli\u003eRare-disease niche, limited competition\u003c\/li\u003e\n\u003cli\u003eDepends on starts and persistence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease launch platform, 2 growth brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc.’s near-term growth is centered on Voxzogo and Palynziq, its two clearest orphan-market engines. In 2024, Voxzogo revenue rose to about $1.1 billion and Palynziq to roughly $0.4 billion, showing strong share in rare-disease niches with more room to penetrate than mass markets. Together, they are BioMarin Pharmaceutical Inc.’s best fit for the BCG “Stars” box: high growth, high share, and still expanding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVoxzogo: largest growth driver\u003c\/li\u003e\n\u003cli\u003ePalynziq: smaller but durable\u003c\/li\u003e\n\u003cli\u003eBoth target orphan markets\u003c\/li\u003e\n\u003cli\u003ePenetration still has runway\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin’s Rare-Disease Stars Keep Shining\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVoxzogo and Palynziq are BioMarin Pharmaceutical Inc.’s Stars: both sit in rare-disease markets with strong growth and clear pricing power. Voxzogo led with about $1.1 billion in 2024 revenue, while Palynziq added about $0.4 billion, and both still have room to expand as diagnosis and access improve in 2025\/2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Revenue\u003c\/th\u003e\n\u003cth\u003eBCG Role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVoxzogo\u003c\/td\u003e\n\u003ctd\u003e$1.1 billion\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePalynziq\u003c\/td\u003e\n\u003ctd\u003e$0.4 billion\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBioMarin’s BCG Matrix maps its drugs into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBioMarin Pharmaceutical Inc. BCG Matrix for quick quadrant clarity and easier portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for BioMarin’s key assumptions, helping users verify claims fast and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVimizim, MPS IVA enzyme replacement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVimizim, approved in 2014 for MPS IVA, is a long-established orphan enzyme therapy with durable demand and a strong niche position. In BioMarin Pharmaceutical Inc.'s 2024 results, it remained part of a portfolio that generated about $2.4 billion in total revenue, supporting steady cash flow. The market is mature and low-growth, but Vimizim still fits the Cash Cows bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNaglazyme, MPS VI franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNaglazyme has been commercial since 2005, so it fits BioMarin Pharmaceutical Inc.'s cash cow profile: mature, steady, and highly focused on a tiny MPS VI market. The franchise keeps recurring revenue with little growth, but its rare-disease position stays structurally strong because treatment options are limited. It is old money, not growth money.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrineura, CLN2 Batten disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrineura targets CLN2 Batten disease in children 3 years and older, with infusions every 2 weeks and few direct substitutes. The patient pool is ultra-small and the market is stable, not fast growing. That makes Brineura a Cash Cow for BioMarin Pharmaceutical Inc., generating recurring cash more than expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAldurazyme, MPS I legacy biologic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAldurazyme remains a mature, low-growth asset in BioMarin Pharmaceutical Inc.'s portfolio. As an MPS I legacy biologic, it still brings in revenue from a tiny, stable patient base, but the runway is capped because new demand is limited and the franchise is long past its high-growth phase.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder, well-known rare-disease therapy\u003c\/li\u003e\n\u003cli\u003eStable demand, weak growth upside\u003c\/li\u003e\n\u003cli\u003eStill cash-generative for BioMarin Pharmaceutical Inc.\u003c\/li\u003e\n\u003cli\u003eFits the cash cow box in BCG terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKuvan, residual PKU revenue base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKuvan is a legacy PKU asset that still throws off cash, even as generic sapropterin pressure keeps sales in decline. PKU affects roughly 1 in 25,000 to 1 in 50,000 births, so the core market is stable, not fast-growing. BioMarin can harvest the remaining revenue base without heavy reinvestment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy asset\u003c\/li\u003e\n\u003cli\u003eCash flow still positive\u003c\/li\u003e\n\u003cli\u003eGrowth now limited\u003c\/li\u003e\n\u003cli\u003eBest use is harvest, not expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin’s Cash Cows Keep Revenue Flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc.'s Cash Cows are its mature rare-disease brands: Vimizim, Naglazyme, Brineura, Aldurazyme, and Kuvan. In 2024, BioMarin Pharmaceutical Inc. generated about $2.4 billion in revenue, and these franchises still deliver steady cash from small, stable patient pools. Growth is limited, but the installed base keeps revenue recurring.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eCash Cow signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVimizim\u003c\/td\u003e\n\u003ctd\u003eDurable niche demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNaglazyme\u003c\/td\u003e\n\u003ctd\u003eMature, steady cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrineura\u003c\/td\u003e\n\u003ctd\u003eUltra-small stable market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBioMarin Pharmaceutical Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact BioMarin Pharmaceutical Inc. BCG Matrix report you’ll receive after purchase. The file is fully formatted, with no watermarks or demo content. What you see here is the same document delivered for immediate use in analysis, presentations, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKuvan, generic erosion and declining share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKuvan has lost strategic weight as BioMarin Pharmaceutical Inc. shifted PKU care to newer options like Palynziq, while generic sapropterin cut pricing power. That mix has kept Kuvan in decline, with management treating it as a non-growth asset. By end-2025, the segment fits a dog profile: weak share, thin economics, and limited reinvestment case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAldurazyme, aging MPS I brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAldurazyme is a mature MPS I enzyme-replacement therapy for a rare disease affecting about 1 in 100,000 births, so the market stays tiny. Its sales are mainly maintenance, not growth, and the brand’s age limits upside. For BioMarin Pharmaceutical Inc., the commercial case for heavy reinvestment is weak, which fits a Dogs profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy non-core collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy non-core collaborations sit in BioMarin Pharmaceutical Inc.'s dog zone: older partnered assets now add little incremental share and get far less capital than core rare-disease drugs. In 2025, BioMarin's growth story stayed centered on newer franchises, while these collaborations remained low-growth and low-priority. That mix usually means weak strategic fit and limited upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSlow-moving mature orphan labels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc.’s slow-moving mature orphan labels are steady cash generators, but their demand is flat and far below the growth pace of Voxzogo, which posted over $1.2 billion in 2025 revenue run-rate, while Palynziq kept growing from a much smaller base. That low-growth profile caps strategic value in a BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable sales, weak expansion\u003c\/li\u003e\n\u003cli\u003eLimited reinvestment priority\u003c\/li\u003e\n\u003cli\u003eLower growth than key stars\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh-cost, low-expansion support sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc.'s mature legacy brands still carry fixed plant, quality, and field-sales costs, so weak volume can keep margins tight. In 2025, this matters most for older enzyme therapies, where flat demand can leave support spend ahead of revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth keeps overhead leverage weak.\u003c\/li\u003e\n\u003cli\u003eSmall volumes still need full support.\u003c\/li\u003e\n\u003cli\u003eMargin upside needs stronger demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat is why these lines fit the Dogs bucket: cash can stay positive, but expansion is limited and cost absorption stays poor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin’s Dog Assets: Low Growth, Limited Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKuvan, Aldurazyme, and legacy collaborations sit in BioMarin Pharmaceutical Inc.’s Dogs bucket: low growth, weak share, and limited reinvestment appeal. Kuvan has lost pricing power after generic sapropterin, while Aldurazyme stays in a tiny market near 1 in 100,000 births. BioMarin Pharmaceutical Inc. kept 2025 growth focused on Voxzogo, which topped $1.2 billion in revenue run-rate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 profile\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKuvan\u003c\/td\u003e\n\u003ctd\u003eGeneric pressure, declining\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAldurazyme\u003c\/td\u003e\n\u003ctd\u003eMature, tiny market\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy collaborations\u003c\/td\u003e\n\u003ctd\u003eLow share, low growth\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValoctocogene roxaparvovec, severe hemophilia A gene therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValoctocogene roxaparvovec is BioMarin Pharmaceutical Inc.’s biggest swing asset: it won U.S. approval in 2023 for adults with severe hemophilia A, a rare disease seen in about 1 in 5,000 male births. But uptake is still uncertain, so it sits squarely in the Question Mark bucket.\u003c\/p\u003e\n\u003cp\u003eHemophilia A is a high-value specialty market because severe patients need lifelong bleed control, yet gene therapy only wins if doctors and payers accept its one-time cost and durability. BioMarin needs real share gains from a small base; without that, the asset may stay a costly bet, not a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMN 307, Phase 1\/2 PKU gene therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBMN 307 is a Phase 1\/2 phenylketonuria gene therapy, so its current market share is 0, but it fits BioMarin Pharmaceutical Inc.’s proven PKU franchise, which generated $2.4 billion in 2024 revenue. If early safety and durability hold, BMN 307 could turn from a question mark into a future star in a market BioMarin already knows well. The main watchpoints are clinical response, safety, and whether it can beat standard PKU treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBMN 255, Phase 1\/2 primary hyperoxaluria\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBMN 255 is still a Question Mark in BioMarin Pharmaceutical Inc.'s BCG Matrix because it is only in Phase 1\/2 for primary hyperoxaluria, an ultra-rare disease with a very small patient pool. Its value is tied to early human proof, since primary hyperoxaluria affects roughly 1 to 3 people per million and even strong efficacy data would still leave a long path to approval and launch. BioMarin's call is simple: if BMN 255 shows clear oxalate reduction and safety in early studies, it can earn a bigger role; if not, the program stays a cash drag.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAAV5 gene therapy platform, no commercial share yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc.'s AAV gene therapy platform is still a question mark: the science gives it a real shot at a large rare-disease market, but it has not yet built meaningful commercial share. Roctavian, its AAV5-based hemophilia A therapy, showed the platform can reach approval, but uptake has been slow and execution risk remains high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge market, no clear share yet\u003c\/li\u003e\n\u003cli\u003eAAV5 is an option, not a winner\u003c\/li\u003e\n\u003cli\u003eApproval proves science; sales must prove scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext-generation rare-disease pipeline, early clinical stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin's early rare-disease programs are question marks: they can become stars only if they show clear efficacy, safety, and payer demand. With 2024 revenue near $2.4 billion and mature products like Vimizim and Naglazyme already slowing, the company needs fresh launches to replace franchise growth. Until those assets clear late-stage risk, they mainly burn R\u0026amp;D cash and stay optionality, not earnings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage assets still need clinical proof\u003c\/li\u003e\n\u003cli\u003eMature franchises need replacement growth\u003c\/li\u003e\n\u003cli\u003eCapital spend stays high before launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin’s Biggest Upside—and Risk—Sits in These Three Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin’s Question Marks are the assets with the most upside and the most risk: Roctavian has U.S. approval but still needs durable sales, while BMN 307 and BMN 255 are early-stage bets with zero market share today. With 2024 revenue near $2.4 billion, BioMarin needs one or more of these programs to prove clinical value and payer demand fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eWhy it is a question mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoctavian\u003c\/td\u003e\n\u003ctd\u003eApproved\u003c\/td\u003e\n\u003ctd\u003eSlow uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMN 307\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2\u003c\/td\u003e\n\u003ctd\u003eNo share yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMN 255\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2\u003c\/td\u003e\n\u003ctd\u003eEarly proof only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234089246985,"sku":"bmrn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bmrn-bcg-matrix.webp?v=1785713337","url":"https:\/\/dcfanalyst.com\/products\/bmrn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}